Consequently, it is anticipated that guideline recommendations will shift towards first-line PSMA PET/CT staging for high-risk and very high-risk cancers, leading clinicians to expect higher sensitivity from PSMA imaging than has been reported. This evidence concerns the gene FOLH1 and cancer.